Zhiya Yu

List of Publications by Year
in descending order

30 papers	5,447 citations	236925 25 h-index	477307 29 g-index
31 all docs	31 docs citations	31 times ranked	8599 citing authors

#	Article	IF	Citations
1	A human memory T cell subset with stem cellâ€“like properties. Nature Medicine, 2011, 17, 1290-1297.	30.7	1,547
2	Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. Journal of Clinical Investigation, 2005, 115, 1616-1626.	8.2	815
3	T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science, 2019, 363, .	12.6	355
4	Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells. Blood, 2010, 116, 3875-3886.	1.4	301
5	Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer. Science, 2020, 370, 1328-1334.	12.6	273
6	T-cell receptor affinity and avidity defines antitumor response and autoimmunity in T-cell immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 6973-6978.	7.1	203
7	Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche. Cell, 2016, 166, 1117-1131.e14.	28.9	203
8	Neoantigen screening identifies broad TP53 mutant immunogenicity in patients with epithelial cancers. Journal of Clinical Investigation, 2019, 129, 1109-1114.	8.2	193
9	Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. Cancer Immunology Research, 2016, 4, 204-214.	3.4	175
10	Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science, 2022, 375, 877-884.	12.6	156
11	The transcription factor c-Myb regulates CD8+ T cell stemness and antitumor immunity. Nature Immunology, 2019, 20, 337-349.	14.5	113
12	Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. JCI Insight, 2018, 3, .	5.0	110
13	Poor immunogenicity of a self/tumor antigen derives from peptideâ€“MHC-I instability and is independent of tolerance. Journal of Clinical Investigation, 2004, 114, 551-559.	8.2	104
14	miR-155 augments CD8 ⁺ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic Î³ _c cytokines. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 476-481.	7.1	99
15	Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies. Cancer Cell, 2020, 37, 818-833.e9.	16.8	96
16	An engineered IL-2 partial agonist promotes CD8+ T cell stemness. Nature, 2021, 597, 544-548.	27.8	94
17	Clinical Scale Zinc Finger Nuclease-mediated Gene Editing of PD-1 in Tumor Infiltrating Lymphocytes for the Treatment of Metastatic Melanoma. Molecular Therapy, 2015, 23, 1380-1390.	8.2	88
18	Antigen Experienced T Cells from Peripheral Blood Recognize p53 Neoantigens. Clinical Cancer Research, 2020, 26, 1267-1276.	7.0	69

#	Article	IF	Citations
19	Poor immunogenicity of a self/tumor antigen derives from peptideâ€“MHC-I instability and is independent of tolerance. Journal of Clinical Investigation, 2004, 114, 551-559.	8.2	66
20	Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer. Oncotarget, 2015, 6, 9073-9085.	1.8	54
21	Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptorâ€“Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors. Cancer Immunology Research, 2022, 10, 932-946.	3.4	52
22	Host conditioning with IL-1Î² improves the antitumor function of adoptively transferred T cells. Journal of Experimental Medicine, 2019, 216, 2619-2634.	8.5	51
23	Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of miceÂbearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation. Cancer Immunology, Immunotherapy, 2019, 68, 1805-1817.	4.2	40
24	An effective mouse model for adoptive cancer immunotherapy targeting neoantigens. JCI Insight, 2019, 4, .	5.0	36
25	Generation of Tumor Antigen-Specific iPSC-Derived Thymic Emigrants Using a 3D Thymic Culture System. Cell Reports, 2018, 22, 3175-3190.	6.4	35
26	Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models. , 2020, 8, e000210.		27
27	Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy. Clinical Cancer Research, 2021, 27, 5084-5095.	7.0	26
28	Identification of the Genomic Insertion Site of Pmel-1 TCR Î± and Î² Transgenes by Next-Generation Sequencing. PLoS ONE, 2014, 9, e96650.	2.5	24
29	Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest. Cancer Immunology Research, 2015, 3, 37-47.	3.4	24
30	Constitutive Lck Activity Drives Sensitivity Differences between CD8+ Memory T Cell Subsets. Journal of Immunology, 2016, 197, 644-654.	0.8	18